ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f4bce6bc-5333-46b7-b13f-e85431649a77"}, "_deposit": {"created_by": 14, "id": "5263", "owners": [14], "pid": {"revision_id": 0, "type": "depid", "value": "5263"}, "status": "published"}, "_oai": {"id": "oai:dmu.repo.nii.ac.jp:00005263", "sets": ["233"]}, "author_link": ["6302", "715", "721", "46596", "10548"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "234", "bibliographicPageStart": "226", "bibliographicVolumeNumber": "1", "bibliographic_titles": [{"bibliographic_title": "Dokkyo Medical Journal"}]}]}, "item_10001_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": " Among the components of renin-angiotensin-aldosterone system, aldosterone facilitates the progression of cardiovascular organ injuries not only by promoting renal tubular Na reabsorption but also by causing oxidative stress, inflammation and cardiovascular tissue hypertrophy and fibrosis. Therefore, mineral corticoid receptor blockers (MRB) supposedly exhibit protective effects against cardiovascular organ injuries in hypertensive patients. In this study, the therapeutic effects of MRB in the combination antihypertensive treatment were examined in hypertensive patients.\n Fifty mg eplerenone (EPL) was added to 24 hypertensive patients under antihypertensive drug therapy who had not achieved the target blood pressure. The combination was continued for 3 to 4 months and the effects on blood pressure (BP) and laboratory data including renal function and cardiovascular endocrine system were evaluated.\n After 3-4 months, office BP was lowered from 148/91 to 135/86 mmHg (p\u003c0.001/p=0.002) as well as the home BP (morning 150/86 to 134/81, p = 0.001/p = 0.033; evening 139/80 to 127/74, p = 0.005/p = 0.030). Serum K (4.2 to 4.3 mEq/L, p = 0.014) and creatinine (0.82 to 0.87 mg/dL, P\u003c0.001) increased slightly but significantly. Serum uric acid also increased significantly from 5.8 to 6.4 mg/dL (p = 0.015). However, the indices of glucose metabolism and serum lipids were not affected. In addition to the natural increases in plasma renin and aldosterone, plasma B-type natriuretic peptide (BNP: 23 to 17 pg/mL, p = 0.028) and urinary albumin excretion (111 to 70 mg/gCr, p = 0.009) were significantly decreased.\n In the combination antihypertensive drug therapy, MRB is expected to reduce cardiac and renal injuries and the influences on glucose and lipid metabolisms seem negligible, however, care should be taken for the development of hyperuricemia and renal dysfunction in addition to hyperkalemia.", "subitem_description_type": "Abstract"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Dokkyo Medical Society"}]}, "item_10001_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.51040/dkmj.2022-030", "subitem_relation_type_select": "DOI"}}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2436-522X", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_text_24": {"attribute_name": "著者所属", "attribute_value_mlt": [{"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}, {"subitem_text_value": "Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan"}]}, "item_10001_text_33": {"attribute_name": "記事種別", "attribute_value_mlt": [{"subitem_text_value": "Original"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Honda, Takeaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "721", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishimitsu, Toshihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "715", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Satonaka, Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6302", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwashima, Yoshio", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "46596", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tojo, Akihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "10548", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-12-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "DKMJ-1-3-10.pdf", "filesize": [{"value": "380.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 380400.0, "url": {"label": "DKMJ-1-3-Honda-Fulltext", "url": "https://dmu.repo.nii.ac.jp/record/5263/files/DKMJ-1-3-10.pdf"}, "version_id": "bbabc97e-b4f3-44e3-833e-d39002d0e460"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "hypertension", "subitem_subject_scheme": "Other"}, {"subitem_subject": "eplerenone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "mineral corticoid receptor blocker", "subitem_subject_scheme": "Other"}, {"subitem_subject": "aldosterone", "subitem_subject_scheme": "Other"}, {"subitem_subject": "albuminuria", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients"}]}, "item_type_id": "10001", "owner": "14", "path": ["233"], "permalink_uri": "https://dmu.repo.nii.ac.jp/records/5263", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-12-26"}, "publish_date": "2022-12-26", "publish_status": "0", "recid": "5263", "relation": {}, "relation_version_is_last": true, "title": ["Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients"], "weko_shared_id": -1}
  1. Dokkyo Medical Journal
  2. 1(3) 2022

Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients

https://dmu.repo.nii.ac.jp/records/5263
https://dmu.repo.nii.ac.jp/records/5263
e94170e4-7531-45b4-b5d2-5bdd0227b29f
名前 / ファイル ライセンス アクション
DKMJ-1-3-10.pdf DKMJ-1-3-Honda-Fulltext (380.4 kB)
license.icon
Item type 学術雑誌論文 / Journal Article(1)
タイトル
タイトル Therapeutic Effects of a Selective Mineralocorticoid Receptor Blocker as an Additional Combination Antihypertensive Drug in Hypertensive Patients
言語
言語 eng
キーワード
主題Scheme Other
主題 hypertension
キーワード
主題Scheme Other
主題 eplerenone
キーワード
主題Scheme Other
主題 mineral corticoid receptor blocker
キーワード
主題Scheme Other
主題 aldosterone
キーワード
主題Scheme Other
主題 albuminuria
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
著者 Honda, Takeaki

× Honda, Takeaki

WEKO 721

en Honda, Takeaki

Search repository
Ishimitsu, Toshihiko

× Ishimitsu, Toshihiko

WEKO 715

en Ishimitsu, Toshihiko

Search repository
Satonaka, Hiroshi

× Satonaka, Hiroshi

WEKO 6302

en Satonaka, Hiroshi

Search repository
Iwashima, Yoshio

× Iwashima, Yoshio

WEKO 46596

en Iwashima, Yoshio

Search repository
Tojo, Akihiro

× Tojo, Akihiro

WEKO 10548

en Tojo, Akihiro

Search repository
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
著者所属
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan
書誌情報 Dokkyo Medical Journal

巻 1, 号 3, p. 226-234, 発行日 2022-09
抄録
内容記述タイプ Abstract
内容記述 Among the components of renin-angiotensin-aldosterone system, aldosterone facilitates the progression of cardiovascular organ injuries not only by promoting renal tubular Na reabsorption but also by causing oxidative stress, inflammation and cardiovascular tissue hypertrophy and fibrosis. Therefore, mineral corticoid receptor blockers (MRB) supposedly exhibit protective effects against cardiovascular organ injuries in hypertensive patients. In this study, the therapeutic effects of MRB in the combination antihypertensive treatment were examined in hypertensive patients.
 Fifty mg eplerenone (EPL) was added to 24 hypertensive patients under antihypertensive drug therapy who had not achieved the target blood pressure. The combination was continued for 3 to 4 months and the effects on blood pressure (BP) and laboratory data including renal function and cardiovascular endocrine system were evaluated.
 After 3-4 months, office BP was lowered from 148/91 to 135/86 mmHg (p<0.001/p=0.002) as well as the home BP (morning 150/86 to 134/81, p = 0.001/p = 0.033; evening 139/80 to 127/74, p = 0.005/p = 0.030). Serum K (4.2 to 4.3 mEq/L, p = 0.014) and creatinine (0.82 to 0.87 mg/dL, P<0.001) increased slightly but significantly. Serum uric acid also increased significantly from 5.8 to 6.4 mg/dL (p = 0.015). However, the indices of glucose metabolism and serum lipids were not affected. In addition to the natural increases in plasma renin and aldosterone, plasma B-type natriuretic peptide (BNP: 23 to 17 pg/mL, p = 0.028) and urinary albumin excretion (111 to 70 mg/gCr, p = 0.009) were significantly decreased.
 In the combination antihypertensive drug therapy, MRB is expected to reduce cardiac and renal injuries and the influences on glucose and lipid metabolisms seem negligible, however, care should be taken for the development of hyperuricemia and renal dysfunction in addition to hyperkalemia.
記事種別
Original
出版者
出版者 Dokkyo Medical Society
ISSN
収録物識別子タイプ ISSN
収録物識別子 2436-522X
DOI
識別子タイプ DOI
関連識別子 10.51040/dkmj.2022-030
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-20 14:44:39.674414
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3